ストックスクリーナーアプリを入手
1.76
5.38%
-0.10
アフターアワーズ：
1.82
0.06
+3.41%
前日終値:
$1.86
開ける：
$1.97
24時間の取引高:
187.46K
Relative Volume:
0.96
時価総額：
$61.01M
収益：
-
当期純損益:
$-13.08M
株価収益率:
-3.9855
EPS:
-0.4416
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-10.66%
1か月 パフォーマンス:
-29.60%
6か月 パフォーマンス:
-62.31%
1年 パフォーマンス:
-68.46%
1日の値動き範囲:
$1.705
$1.97
1週間の範囲:
$1.705
$2.05
52週間の値動き範囲:
$1.705
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
TELO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.76 | 61.01M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-21 | 開始されました | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc (TELO) 最新ニュース
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeriaan Ultra-Rare Genetic Disorder that Causes Rapid Aging - Knoxville News Sentinel
# Telomir-1 shows anti-aging effects in progeria cell study By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals reports positive results for progeria treatment - Investing.com
# Telomir-1 shows anti-aging effects in progeria cell study - Investing.com Australia
Telomir Pharmaceuticals IncTelomir-1 Significantly Increased Cell ViabilitySEC Filing - marketscreener.com
Revolutionary Progeria Treatment Shows First-Ever Cellular Aging Prevention in Children's Cells - Stock Titan
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria - Benzinga
TELO Rises on Promising Telomir-1 Preclinical Results - MSN
10 Best Growth Stocks Under $100 to Buy Now - Insider Monkey
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model - The Oklahoman
Telomir-1 shows promise in reversing Wilson’s disease symptoms By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports promising drug trial results By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports promising drug trial results - Investing.com
Telomir Pharmaceuticals Says Positive Preclinical Results For Telomir-1 In Wilson'S Disease Animal Model - marketscreener.com
Telomir-1 shows promise in reversing Wilson’s disease symptoms - Investing.com Australia
Breakthrough Wilson's Disease Treatment Reverses Brain, Liver, and Kidney Damage in Preclinical Study - Stock Titan
Nuveen Asset Management LLC Purchases New Shares in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome - Reno Gazette Journal
telomir pharmaceuticals reports promising preclinical results for telomir-1 By Investing.com - Investing.com South Africa
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder - AOL.com
Telomir Says Lead Candidate Telomir-1 Restored Gene Regulation in Animal Model of Werner Syndrome - marketscreener.com
telomir pharmaceuticals reports promising preclinical results for telomir-1 - Investing.com
Telomir Pharmaceuticals-New Data From Preclinical Study Of Its Lead Compound, Telomir-1, In Validated Animal Model Of Werner Syndrome - marketscreener.com
Revolutionary Anti-Aging Drug Resets Biological Clock, Reverses Multiple Aging Markers in Landmark Study - Stock Titan
Telomir Pharmaceuticals Joins BIO Convention for Partnerships - MSN
Telomir announces positive preclinical data for its novel oral AMD therapeutic - Ophthalmology Times
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - Cheboygan Daily Tribune
Telomir Pharmaceuticals To Present At BIO 2025, Eyes IND Filing For Telomir-1 - Nasdaq
Revolutionary Anti-Aging Drug Telomir-1 Heads to FDA Review: Multiple Disease Applications Revealed - Stock Titan
TELO stock touches 52-week low at $1.96 amid market challenges By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Inc (TELO) 財務データ
収益
当期純利益
現金流量
EPS
2.13%
1.01%
大文字化:
|
ボリューム (24 時間):